FCGR3A /2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts-Reference-Cited by-同舟云学术

FCGR3A /2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts

Published:2016-06-10 Issue:4 Volume:35 Page:447-455
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Ghesquières Hervé¹²³,Larrabee Beth R.³,Haioun Corinne⁴,Link Brian K.⁵,Verney Aurélie²,Slager Susan L.³,Ketterer Nicolas⁶,Ansell Stephen M.⁷,Delarue Richard⁸,Maurer Matthew J.³,Fitoussi Olivier⁹,Habermann Thomas M.⁷,Peyrade Fréderic¹⁰,Dogan Ahmet¹¹,Molina Thierry J.¹²,Novak Anne J.³,Tilly Hervé¹³,Cerhan James R.³,Salles Gilles¹²

Affiliation:

1. Department of Hematology; Centre Hospitalier Lyon Sud; Pierre-Bénite France

2. Centre de Recherche en Cancérologie de Lyon - INSERM U 1052/CNRS UMR 5286/Centre Léon Bérard; Lyon France

3. Department of Health Sciences Research; Mayo Clinic; Rochester MN USA

4. Lymphoid Malignancies Unit, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP) and University Paris Est; Créteil France

5. Holden Comprehensive Cancer Center; University of Iowa; Iowa City IA USA

6. Department of Oncology; University Hospital; Lausanne Switzerland

7. Division of Hematology, Department of Internal Medicine; Mayo Clinic; Rochester MN USA

8. Department of Hematology; Necker Hospital; Paris France

9. Onco-Hematology, Polyclinique Bordeaux-Nord; Bordeaux France

10. Medical Oncology, Centre Antoine Lacassagne; Nice France

11. Departments of Pathology and Laboratory Medicine; Memorial Sloan Kettering Cancer Center; New York NY USA